Drugs / CGT4859
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06777316 | Jan 2025 → Mar 2027 expected | intrahepatic cholangiocarcinoma | Cogent Biosciences, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGT4859 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06777316 ↗ |
| Action | Inhibit | “CGT4859 is a selective FGFR2/3 inhibitor” NCT06777316 ↗ |
| Route | Oral | “Multiple doses of CGT4859 for oral administration” NCT06777316 ↗ |
| Target | FGFR2 | “CGT4859 is a selective FGFR2/3 inhibitor” NCT06777316 ↗ |